Trial
CANTOS
Trial testing IL-1β inhibition with canakinumab in inflammatory cardiovascular disease.
Also called: CANTOS trial, Canakinumab Anti-inflammatory Thrombosis Outcomes Study
In short
- 1What it is: a trial in therapies and applications.
- 2How it connects: acts on 3 and is affected by 0 concepts — mostly 1 molecule, 1 pathway, 1 therapy.
- 3Where it sits: trial on the 15-step immune chain.
What it does
N=10,061; canakinumab (anti-IL-1β) vs placebo in post-MI patients with hsCRP >2mg/L; MACE -15% (HR 0.85, p=0.021); LDL unchanged → first clinical proof macrophage NLRP3-IL-1β causally drives CVD (not just lipid storage); lung cancer mortality -77% (unexpected, IL-1β promotes TME); colchicine (COLCOT: -23%; LoDoCo-2: -31%) validated same mechanism cheaply
Its connections at a glance
Each dot is a concept directly linked to CANTOS. Colours show the kind of concept.
Sources & evidenceloading…
Loading reviewed sources…
Graph ID TR002 · concept status: established. Select any connection above to inspect evidence for that specific link.